• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: COVIDIEN SPIDER FX; TEMPORARY CAROTID CATHETER FOR EMBOLIC CAPTURE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

COVIDIEN SPIDER FX; TEMPORARY CAROTID CATHETER FOR EMBOLIC CAPTURE Back to Search Results
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Perforation (2001); Vascular Dissection (3160); Embolism/Embolus (4438)
Event Date 10/28/2021
Event Type  Injury  
Event Description
A journal article was submitted detailing a study which investigated the outcomes of atherectomy plus dcb (a+dcb) compared with dcb alone for the treatment of femoropopliteal artery disease.In the a+dcb group, two types of atherectomy devices were used, directional devices (59.8%) and rotational devices (40.2%).Embolization protection filters were used in 65.9% of the a+dcb group.311 patients (348 limbs) were included in the study.Of these, 82 limbs were treated with a+dcb and 266 limbs with dcb alone.Medtronic¿s spiderfx and in.Pact admiral devices were used during the study.The in.Pact admiral dcb was used in approximately 70% of cases.In lesions requiring more than one dcb, a minimal overlap of 10 mm was obtained.If residual stenosis exceeded 30%, post-dilation was performed with an additional uncoated non-compliant balloon.Stenting was considered only as a last resort in the presence of flow-limiting dissection or when residual stenosis exceeded 30% despite post-dilation.Technical success is reported in 80.15% of the a+dcb group and 69.2% in the dcb alone group.Procedural related minor complications of arterial dissection, distal embolization, and vascular perforation are reported.Patients were clinically followed for a mean duration of 24.8±14.3 months.The 2-year primary clinical patency did not differ significantly between the a+dcb and the dcb group.Similarly, 2-year tlr-free survival was also not different between the two groups.The rates of mortality and the male at 2 years showed no difference between the two groups.There is no established or suspected causal relationship between the device(s) and the death events.
 
Manufacturer Narrative
Title: clinical outcomes of atherectomy plus drug-coated balloon versus drug-coated balloon alone in the treatment of femoropopliteal artery disease author: jung-joon cha, jae-hwan lee, young-guk ko journal: korean circulation journal year: 2021.Vol/issue: 52:e1 ref: doi: 10.4070/kcj.2021.0246.Date of publication journal reported death but there is no information to suggest the device caused or contributed to the death events.Deaths are common occurrences in clinical studies, however the cause(s) of death are often not characterized or clearly associated with a particular product.Therefore, deaths will not be considered reportable unless clearly stated as being associated with a medtronic device.If information is provided in the future, a supplemental report will be issued.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
SPIDER FX
Type of Device
TEMPORARY CAROTID CATHETER FOR EMBOLIC CAPTURE
Manufacturer (Section D)
COVIDIEN
4600 nathan lane north
plymouth MN 55442
Manufacturer (Section G)
COVIDIEN
4600 nathan lane north
plymouth MN 55442
Manufacturer Contact
toni o'doherty
parkmore business park west
galway 
EI  
091708734
MDR Report Key13150173
MDR Text Key288794479
Report Number2183870-2022-00002
Device Sequence Number1
Product Code NTE
Combination Product (y/n)N
Reporter Country CodeKS
PMA/PMN Number
K111010
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Foreign,Literature,Health Professional,Company Representative
Reporter Occupation Physician
Type of Report Initial
Report Date 01/04/2022
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received01/04/2022
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received12/15/2021
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
Patient Age70 YR
Patient SexMale
-
-